IndustryCompany release

Valion Bio opens preliminary sale talks for Velocity Bioworks CDMO after unsolicited approaches

🇺🇸 Valion Bio, Inc. (VBIO) · Mon 26 Oct 2026

The Nasdaq-listed company says third parties have approached it about its biologics contract manufacturer and that it has hired an investment bank, with no sale yet agreed.

Valion Bio (NASDAQ: VBIO) said on 26 October 2026 that independent third parties had made unsolicited inquiries about acquiring Velocity Bioworks, its wholly owned biologics contract development and manufacturing organisation (CDMO). Preliminary discussions have begun, according to the company.

Valion has engaged an investment bank in connection with the process. It stressed that it has not committed to a sale of the unit.

The company said any transaction would have to preserve production rights and continued manufacturing capacity for its lead candidate, Entolimod. Entolimod is a TLR5 agonist being developed for Acute Radiation Syndrome under the FDA Animal Rule.

As general context, the Animal Rule allows the US Food and Drug Administration to consider efficacy evidence from animal studies when human efficacy trials would be unethical or infeasible, which makes secure, consistent manufacturing a central part of such programmes.

Valion does not plan to provide further updates unless a definitive agreement is reached or disclosure is otherwise required.

What it means for your team

  • Quality and supply teams should note that a change of ownership at a CDMO can affect manufacturing arrangements, so supply-continuity provisions matter in any deal.
  • Regulatory teams should watch for any later filings or notices that could affect manufacturing sites or responsibilities linked to Entolimod.
  • Valion has said a deal would need to protect Entolimod production rights and capacity, but no sale has been agreed and no timetable has been given.

Company's press release (SEC filing): Valion Bio, Inc. ↗

Article written by VigiEye from the official source (Valion Bio, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →